Aftx FIA arrests official of interior ministry
Cangene Corporation reports that it has signed a new agreement with its majority shareholder, the Apotex Group. Since 1995, under an existing agreement, Apotex has funded research and development of several recombinant biopharmaceutical products at Cangene; these funding obligations have been satisfied.Under the new agreement, Cangene obtains rights to commercialize these products, which include Leucotropin庐, Cangene's version of a white-blood-cell-stimulating damen jordans protein known as GM-CSF, and Accretropin鈩? Cangene's human growth hormone. Due to the extent of Apotex's investment in the two lead drugs, however, both companies have the right to take Leucotropin庐 yeezy boost or Accretropin鈩?to market and would pay th dunk panda e other company a small royalty based on any sales."Apotex has played a large role in the development of certain products over the years, but recently both of us have been incr